Systemic sclerosis

The Lancet

Volumn 390, Issue 10103, 2017, Pages 1685-1699

  Denton, Christopher P ^a,b   Khanna, Dinesh ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

ADRENAL CORTEX INSUFFICIENCY; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DYSPNEA; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENETIC SUSCEPTIBILITY; GLOSSOPHARYNGEAL NEURALGIA; HEART DISEASE; HUMAN; LONG TERM SURVIVAL; LUNG FIBROSIS; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; NEUROPATHY; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SKIN DISEASE; SWELLING; SYSTEMIC SCLEROSIS; TRIGEMINUS NEURALGIA; COMPLICATION; EVIDENCE BASED MEDICINE; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; SURVIVAL ANALYSIS;

EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSION; SCLERODERMA, SYSTEMIC; SURVIVAL ANALYSIS;

EID: 85017469832     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30933-9     Document Type: Review

References (165)

1. Nihtyanova, SI, Tang, EC, Coghlan, JG, Wells, AU, Black, CM, Denton, CP, Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 103 (2010), 109–115.
2. Tyndall, AJ, Bannert, B, Vonk, M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69 (2010), 1809–1815.
3. Denton, CP, Advances in pathogenesis and treatment of systemic sclerosis. Clin Med 15:suppl 6 (2015), s58–s63.
4. Khanna, D, Furst, DE, Allanore, Y, et al. Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. Rheumatology 54 (2015), 144–151.
5. Chung, L, Denton, CP, Distler, O, Furst, DE, Khanna, D, Merkel, PA, the Scleroderma Clinical Trials Consortium. Clinical trial design in scleroderma: where are we and where do we go next?. Clin Exp Rheumatol 30:suppl 71 (2012), S97–S102.
6. Nihtyanova, SI, Schreiber, BE, Ong, VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 66 (2014), 1625–1635.
7. Jaeger, VK, Wirz, EG, Allanore, Y, et al., the EUSTAR co-authors. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One, 11, 2016, e0163894.
8. Martyanov, V, Whitfield, ML, Molecular stratification and precision medicine in systemic sclerosis from genomic and proteomic data. Curr Opin Rheumatol 28 (2016), 83–88.
9. Rongioletti, F, Kaiser, F, Cinotti, E, et al. Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients. J Eur Acad Dermatol Venereol 29 (2015), 2399–2404.
10. van den Hombergh, WM, Carreira, PE, Knaapen-Hans, HK, van den Hoogen, FH, Fransen, J, Vonk, MC, An easy prediction rule for diffuse cutaneous systemic sclerosis using only the timing and type of first symptoms and auto-antibodies: derivation and validation. Rheumatology 55 (2016), 2023–2032.
11. Guiducci, S, Bellando-Randone, S, Matucci-Cerinic, M, A new way of thinking about systemic sclerosis: the opportunity for a very early diagnosis. Isr Med Assoc J 18 (2016), 141–143.
12. Bellando-Randone, S, Guiducci, S, Matucci-Cerinic, M, Very early diagnosis of systemic sclerosis. Pol Arch Med Wewn 122:suppl 1 (2012), 18–23.
13. Domsic, RT, Nihtyanova, SI, Wisniewski, SR, et al. Derivation and validation of a prediction rule for two-year mortality in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 66 (2014), 1616–1624.
14. Cavagna, L, Codullo, V, Ghio, S, et al. Undiagnosed connective tissue diseases: high prevalence in pulmonary arterial hypertension patients. Medicine, 95, 2016, e4827.
15. van den Hoogen, F, Khanna, D, Fransen, J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65 (2013), 2737–2747.
16. Jordan, S, Maurer, B, Toniolo, M, Michel, B, Distler, O, Performance of the new ACR/EULAR classification criteria for systemic sclerosis in clinical practice. Rheumatology 54 (2015), 1454–1458.
17. Andréasson, K, Saxne, T, Bergknut, C, Hesselstrand, R, Englund, M, Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria. Ann Rheum Dis 73 (2014), 1788–1792.
18. Minier, T, Guiducci, S, Bellando-Randone, S, et al., the EUSTAR co-workers. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 73 (2014), 2087–2093.
19. Lambova, S, Hermann, W, Muller-Ladner, U, Nailfold capillaroscopy—its role in diagnosis and differential diagnosis of microvascular damage in systemic sclerosis. Curr Rheumatol Rev 9 (2013), 254–260.
20. Allanore, Y, Simms, R, Distler, O, et al. Systemic sclerosis. Nat Rev Dis Primers, 1, 2015, 15002.
21. Codullo, V, Cereda, E, Crepaldi, G, et al. Disease-related malnutrition in systemic sclerosis: evidences and implications. Clin Exp Rheumatol 33:suppl 91 (2015), S190–S194.
22. Shand, L, Lunt, M, Nihtyanova, S, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 56 (2007), 2422–2431.
23. Tyndall, A, Fistarol, S, The differential diagnosis of systemic sclerosis. Curr Opin Rheumatol 25 (2013), 692–699.
24. Hughes, M, Ong, VH, Anderson, ME, et al. Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. Rheumatology 54 (2015), 2015–2024.
25. Pakozdi, A, Nihtyanova, S, Moinzadeh, P, Ong, VH, Black, CM, Denton, CP, Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J Rheumatol 38 (2011), 2406–2409.
26. Pakozdi, A, Wilson, H, Black, CM, Denton, CP, Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?. Clin Exp Rheumatol 27:suppl 54 (2009), 5–8.
27. Bissell, LA, Abignano, G, Emery, P, Del Galdo, F, Buch, MH, Absence of scleroderma pattern at nail fold capillaroscopy valuable in the exclusion of scleroderma in unselected patients with Raynaud's phenomenon. BMC Musculoskelet Disord, 17, 2016, 342.
28. Wirz, EG, Jaeger, VK, Allanore, Y, et al., the EUSTAR co-authors. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis 75 (2016), 1285–1292.
29. Diab, S, Dostrovsky, N, Hudson, M, et al., the Canadian Scleroderma Research Group. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects. J Rheumatol 41 (2014), 2179–2185.
30. Lepri, G, Guiducci, S, Bellando-Randone, S, et al. Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. Ann Rheum Dis 74 (2015), 124–128.
31. Kranenburg, P, van den Hombergh, WM, Knaapen-Hans, HK, van den Hoogen, FH, Fransen, J, Vonk, MC, Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study. Rheumatology 55 (2016), 2001–2008.
32. Moinzadeh, P, Nihtyanova, SI, Howell, K, Ong, VH, Denton, CP, Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma. Clin Rev Allergy Immunol 43 (2012), 249–255.
33. Foocharoen, C, Netwijitpan, S, Mahakkanukrauh, A, Suwannaroj, S, Nanagara, R, Clinical characteristics of scleroderma overlap syndromes: comparisons with pure scleroderma. Int J Rheum Dis 19 (2016), 913–923.
34. Penn, H, Howie, AJ, Kingdon, EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 100 (2007), 485–494.
35. Bhattacharyya, S, Wei, J, Varga, J, Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 8 (2011), 42–54.
36. Bossini-Castillo, L, López-Isac, E, Mayes, MD, Martín, J, Genetics of systemic sclerosis. Semin Immunopathol 37 (2015), 443–451.
37. Murdaca, G, Contatore, M, Gulli, R, Mandich, P, Puppo, F, Genetic factors and systemic sclerosis. Autoimmun Rev 15 (2016), 427–432.
38. Assassi, S, Radstake, TR, Mayes, MD, Martin, J, Genetics of scleroderma: implications for personalized medicine?. BMC Med, 11, 2013, 9.
39. Makino, T, Jinnin, M, Genetic and epigenetic abnormalities in systemic sclerosis. J Dermatol 43 (2016), 10–18.
40. Manetti, M, Matucci-Cerinic, M, The new frontier in systemic sclerosis: from epigenetics to new treatments. Rheumatology 54 (2015), 1757–1758.
41. Altorok, N, Kahaleh, B, Epigenetics and systemic sclerosis. Semin Immunopathol 37 (2015), 453–462.
42. Feghali-Bostwick, C, Medsger, TA Jr, Wright, TM, Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 48 (2003), 1956–1963.
43. Salazar, G, Mayes, MD, Genetics, epigenetics, and genomics of systemic sclerosis. Rheum Dis Clin North Am 41 (2015), 345–366.
44. Pollard, KM, Silica, silicosis, and autoimmunity. Front Immunol, 7, 2016, 97.
45. Bossini-Castillo, L, López-Isac, E, Martín, J, Immunogenetics of systemic sclerosis: defining heritability, functional variants and shared-autoimmunity pathways. J Autoimmun 64 (2015), 53–65.
46. Black, CM, Welsh, KI, Walker, AE, et al. Genetic susceptibility to scleroderma-like syndrome induced by vinyl chloride. Lancet 1 (1983), 53–55.
47. De Martinis, M, Ciccarelli, F, Sirufo, MM, Ginaldi, L, An overview of environmental risk factors in systemic sclerosis. Expert Rev Clin Immunol 12 (2016), 465–478.
48. Marie, I, Gehanno, JF, Environmental risk factors of systemic sclerosis. Semin Immunopathol 37 (2015), 463–473.
49. Ogawa, T, Okiyama, N, Koguchi-Yoshioka, H, Fujimoto, M, Taxane-induced scleroderma-like skin changes resulting in gangrene: a case report. J Dermatol, 2016, 10.1111/1346-8138.13569.
50. Hong, C, Sangle, SR, Coghlan, JG, D'Cruz, DP, Scleroderma and breast implants. QJM 108 (2015), 569–570.
51. Konishi, Y, Sato, H, Sato, N, Fujimoto, T, Fukuda, J, Tanaka, T, Scleroderma-like cutaneous lesions induced by paclitaxel and carboplatin for ovarian carcinoma, not a single course of carboplatin, but re-induced and worsened by previously administrated paclitaxel. J Obstet Gynaecol Res 36 (2010), 693–696.
52. Al Aranji, G, White, D, Solanki, K, Scleroderma renal crisis following silicone breast implant rupture: a case report and review of the literature. Clin Exp Rheumatol 32 (2014), 262–266.
53. Bessis, D, Guillot, B, Legouffe, E, Guilhou, JJ, Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol 51:suppl (2004), S73–S76.
54. Motegi, S, Hattori, T, Tago, O, Shimizu, A, Ishikawa, O, Systemic sclerosis associated with silicone breast implantation. Eur J Dermatol 23 (2013), 894–895.
55. Bernstein, EJ, Schmidt-Lauber, C, Kay, J, Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. Best Pract Res Clin Rheumatol 26 (2012), 489–503.
56. Sargent, JL, Li, Z, Aliprantis, AO, et al. Identification of optimal mouse models of systemic sclerosis by interspecies comparative genomics. Arthritis Rheumatol 68 (2016), 2003–2015.
57. Hinz, B, Phan, SH, Thannickal, VJ, et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol 180 (2012), 1340–1355.
58. Wang, Z, Nakamura, K, Jinnin, M, et al. Establishment and gene expression analysis of disease-derived induced pluripotent stem cells of scleroderma. J Dermatol Sci 84 (2016), 186–196.
59. Wu, M, Assassi, S, Salazar, GA, et al. Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. Arthritis Res Ther, 18, 2016, 20.
60. Gilbane, AJ, Denton, CP, Holmes, AM, Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther, 15, 2013, 215.
61. Mahoney, JM, Taroni, J, Martyanov, V, et al. Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. PLoS Comput Biol, 11, 2015, e1004005.
62. Dobrota, R, Maurer, B, Graf, N, et al., the EUSTAR co-authors. Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. Ann Rheum Dis 75 (2016), 1743–1748.
63. Castelino, FV, Varga, J, Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy. Curr Opin Rheumatol 26 (2014), 607–614.
64. Shah, AA, Rosen, A, Hummers, L, Wigley, F, Casciola-Rosen, L, Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 62 (2010), 2787–2795.
65. Airo, P, Ceribelli, A, Cavazzana, I, Taraborelli, M, Zingarelli, S, Franceschini, F, Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 38 (2011), 1329–1334.
66. Joseph, CG, Darrah, E, Shah, AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343 (2014), 152–157.
67. Moinzadeh, P, Fonseca, C, Hellmich, M, et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther, 16, 2014, R53.
68. Denton, CP, Hughes, M, Gak, N, et al. the BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology 55 (2016), 1906–1910.
69. Komócsi, A, Vorobcsuk, A, Faludi, R, et al. The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology 51 (2012), 1027–1036.
70. Kowal-Bielecka, O, Fransen, J, Avouac, J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis, 2016 published online Nov 9. DOI:10.1136/annrheumdis-2016-209909.
71. Coghlan, JG, Denton, CP, Grünig, E, et al., the DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73 (2014), 1340–1349.
72. Domsic, RT, Nihtyanova, SI, Wisniewski, SR, et al. Derivation and external validation of a prediction rule for five-year mortality in patients with early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 68 (2016), 993–1003.
73. Lynch, BM, Stern, EP, Ong, V, Harber, M, Burns, A, Denton, CP, UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis. Clin Exp Rheumatol 34:suppl 100 (2016), 106–109.
74. van der Heijde, D, Aletaha, D, Carmona, L, et al. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 74 (2015), 8–13.
75. Racine, M, Hudson, M, Baron, M, Nielson, WR, the Canadian Scleroderma Research Group. The impact of pain and itch on functioning and health-related quality of life in systemic sclerosis: an exploratory study. J Pain Symptom Manage 52 (2016), 43–53.
76. Razykov, I, Levis, B, Hudson, M, Baron, M, Thombs, BD, the Canadian Scleroderma Research Group. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis: an updated analysis of 959 patients. Rheumatology 52 (2013), 2056–2061.
77. Herrick, AL, Lunt, M, Whidby, N, et al. Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol 37 (2010), 116–124.
78. Maurer, B, Graf, N, Michel, BA, et al., the EUSTAR co-authors. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 74 (2015), 1124–1131.
79. Nihtyanova, SI, Brough, GM, Black, CM, Denton, CP, Mycophenolate mofetil in diffuse cutaneous systemic sclerosis— a retrospective analysis. Rheumatology 46 (2007), 442–445.
80. Le, EN, Wigley, FM, Shah, AA, Boin, F, Hummers, LK, Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 70 (2011), 1104–1107.
81. van den Hoogen, FH, Boerbooms, AM, Swaak, AJ, Rasker, JJ, van Lier, HJ, van de Putte, LB, Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 35 (1996), 364–372.
82. Pope, JE, Bellamy, N, Seibold, JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44 (2001), 1351–1358.
83. Tashkin, DP, Elashoff, R, Clements, PJ, et al., the Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354 (2006), 2655–2666.
84. Morrisroe, KB, Nikpour, M, Proudman, SM, Musculoskeletal manifestations of systemic sclerosis. Rheum Dis Clin North Am 41 (2015), 507–518.
85. Del Papa, N, Onida, F, Zaccara, E, et al. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. Bone Marrow Transplant 52 (2017), 53–58.
86. Burt, RK, Shah, SJ, Dill, K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378 (2011), 498–506.
87. van Laar, JM, Farge, D, Sont, JK, et al., the EBMT/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311 (2014), 2490–2498.
88. Burt, RK, Oliveira, MC, Shah, SJ, et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet 381 (2013), 1116–1124.
89. Sullivan, K, Keyes-Elstein, L, McSweeney, P, et al. Myeloablative autologous transplantation of CD34+-selected hematopoietic stem cells (HSCT) vs monthly intravenous cyclophosphamide (CYC) for severe scleroderma with internal organ involvement: outcomes of a randomized North American clinical trial. Arthritis Rheumatol, 68(suppl 10), 2016 (abstr).
90. Khanna, D, Nagaraja, V, Tseng, CH, et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res Ther, 17, 2015, 372.
91. Khanna, D, Tseng, CH, Farmani, N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 63 (2011), 3078–3085.
92. Goh, NS, Desai, SR, Veeraraghavan, S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177 (2008), 1248–1254.
93. Goh, NS, Desai, SR, Anagnostopoulos, C, et al. Increased epithelial permeability in pulmonary fibrosis in relation to disease progression. Eur Respir J 38 (2011), 184–190.
94. Tashkin, DP, Elashoff, R, Clements, PJ, et al., the Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176 (2007), 1026–1034.
95. Tashkin, DP, Roth, MD, Clements, PJ, et al., the Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4 (2016), 708–719.
96. Panopoulos, ST, Bournia, VK, Trakada, G, Giavri, I, Kostopoulos, C, Sfikakis, PP, Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. Lung 191 (2013), 483–489.
97. Denton, CP, Scleroderma Lung Study II—clarity or obfuscation?. Lancet Respir Med 4 (2016), 678–679.
98. Khanna, D, Albera, C, Fischer, A, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol 43 (2016), 1672–1679.
99. Keir, GJ, Maher, TM, Hansell, DM, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 40 (2012), 641–648.
100. Sobanski, V, Giovannelli, J, Lynch, BM, et al. Characteristics and survival of anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol 68 (2016), 484–493.
101. Hinchcliff, M, Khanna, S, Hsu, VM, et al., the PHAROS Investigators. Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry. Semin Arthritis Rheum 45 (2015), 309–314.
102. Khanna, D, Gladue, H, Channick, R, et al., the Scleroderma Foundation and Pulmonary Hypertension Association. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 65 (2013), 3194–3201.
103. Humbert, M, Coghlan, JG, Ghofrani, HA, et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 76 (2017), 422–426.
104. Fischer, A, Denton, CP, Matucci-Cerinic, M, et al. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH)—a subgroup analysis of the ARIES-E clinical trial. Respir Med 117 (2016), 254–263.
105. Visovatti, SH, Distler, O, Coghlan, JG, et al. Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. Arthritis Res Ther, 16, 2014, 493.
106. Valerio, CJ, Schreiber, BE, Handler, CE, Denton, CP, Coghlan, JG, Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum 65 (2013), 1074–1084.
107. Galiè, N, Humbert, M, Vachiery, JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 46 (2015), 903–975.
108. Sitbon, O, Channick, R, Chin, KM, et al., the GRIPHON Investigators. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373 (2015), 2522–2533.
109. Galiè, N, Barberà, JA, Frost, AE, et al., the AMBITION Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 373 (2015), 834–844.
110. Pulido, T, Adzerikho, I, Channick, RN, et al., the SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369 (2013), 809–818.
111. Shreiner, A, Murray, C, Denton, C, Khanna, D, Gastrointestinal manifestations of systemic sclerosis. J Scleroderma Relat Disord 1 (2016), 247–256.
112. Thoua, NM, Abdel-Halim, M, Forbes, A, Denton, CP, Emmanuel, AV, Fecal incontinence in systemic sclerosis is secondary to neuropathy. Am J Gastroenterol 107 (2012), 597–603.
113. Thoua, NM, Bunce, C, Brough, G, Forbes, A, Emmanuel, AV, Denton, CP, Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre. Rheumatology 49 (2010), 1770–1775.
114. Hansi, N, Thoua, N, Carulli, M, et al. Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis. Clin Exp Rheumatol 32:suppl 86 (2014), S-214–S-221.
115. Thoua, NM, Derrett-Smith, EC, Khan, K, Dooley, A, Shi-Wen, X, Denton, CP, Gut fibrosis with altered colonic contractility in a mouse model of scleroderma. Rheumatology 51 (2012), 1989–1998.
116. Raja, J, Nihtyanova, SI, Murray, CD, Denton, CP, Ong, VH, Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology 55 (2016), 115–119.
117. Rosato, E, Gigante, A, Gasperini, ML, et al. Nutritional status measured by BMI is impaired and correlates with left ventricular mass in patients with systemic sclerosis. Nutrition 30 (2014), 204–209.
118. Codullo, V, Cereda, E, Klersy, C, et al. Serum prealbumin is an independent predictor of mortality in systemic sclerosis outpatients. Rheumatology 55 (2016), 315–319.
119. Bharadwaj, S, Tandon, P, Gohel, T, et al. Gastrointestinal manifestations, malnutrition, and role of enteral and parenteral nutrition in patients with scleroderma. J Clin Gastroenterol 49 (2015), 559–564.
120. Guillevin, L, Bérezné, A, Seror, R, et al. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology 51 (2012), 460–467.
121. Penn, H, Quillinan, N, Khan, K, et al. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM 106 (2013), 839–848.
122. Hudson, M, Baron, M, Tatibouet, S, Furst, DE, Khanna, D, the International Scleroderma Renal Crisis Study Investigators. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis—results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum 43 (2014), 666–672.
123. Chighizola, CB, Pregnolato, F, Meroni, PL, Denton, CP, Ong, VH, N-terminal pro brain natriuretic peptide as predictor of outcome in scleroderma renal crisis. Clin Exp Rheumatol 34:suppl 100 (2016), 122–128.
124. Turk, M, Pope, JE, The frequency of scleroderma renal crisis over time: a metaanalysis. J Rheumatol 43 (2016), 1350–1355.
125. Devresse, A, Aydin, S, Le Quintrec, M, et al. Complement activation and effect of eculizumab in scleroderma renal crisis. Medicine, 95, 2016, e4459.
126. Avouac, J, Meune, C, Chenevier-Gobeaux, C, et al. Cardiac biomarkers in systemic sclerosis: contribution of high-sensitivity cardiac troponin in addition to N-terminal pro-brain natriuretic peptide. Arthritis Care Res 67 (2015), 1022–1030.
127. Hachulla, E, Clerson, P, Airò, P, et al., the EUSTAR co-workers. Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. Rheumatology 54 (2015), 1262–1269.
128. Vacca, A, Meune, C, Gordon, J, et al., the Scleroderma Clinical Trial Consortium Cardiac Subcommittee. Cardiac arrhythmias and conduction defects in systemic sclerosis. Rheumatology 53 (2014), 1172–1177.
129. Bernardo, P, Conforti, ML, Bellando-Randone, S, et al. Implantable cardioverter defibrillator prevents sudden cardiac death in systemic sclerosis. J Rheumatol 38 (2011), 1617–1621.
130. Mueller, KA, Mueller, II, Eppler, D, et al. Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy. PLoS One, 10, 2015, e0126707.
131. Crincoli, V, Fatone, L, Fanelli, M, et al. Orofacial manifestations and temporomandibular disorders of systemic scleroderma: an observational study. Int J Mol Sci, 17, 2016, E1189.
132. Nihtyanova, SI, Brough, GM, Black, CM, Denton, CP, Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 67 (2008), 120–123.
133. Mihai, C, Landewé, R, van der Heijde, D, et al., the EUSTAR co-authors. Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis 75 (2016), 681–686.
134. Allanore, Y, Denton, CP, Krieg, T, et al., the DUO Investigators. Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort. Ann Rheum Dis 75 (2016), 1736–1740.
135. Herrick, AL, van den Hoogen, F, Gabrielli, A, et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 63 (2011), 775–782.
136. Ngcozana, T, Ong, V, Denton, CP, Management of digital vasculopathy in systemic sclerosis: benefits of multiple courses of endothelin-1 receptor antagonists. BMJ Case Rep, 2014, 2014 bcr2013203174.
137. Matucci-Cerinic, M, Krieg, T, Guillevin, L, et al. Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. Ann Rheum Dis 75 (2016), 1770–1776.
138. Khanna, D, Denton, CP, Merkel, PA, et al., the DUAL-1 Investigators. Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials. JAMA 315 (2016), 1975–1988.
139. Matucci-Cerinic, M, Denton, CP, Furst, DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70 (2011), 32–38.
140. Chung, L, Valenzuela, A, Fiorentino, D, et al., the Scleroderma Clinical Trials Consortium Calcinosis Working Group. Validation of a novel radiographic scoring system for calcinosis affecting the hands of patients with systemic sclerosis. Arthritis Care Res 67 (2015), 425–430.
141. Baron, M, Pope, J, Robinson, D, et al. Calcinosis is associated with digital ischaemia in systemic sclerosis—a longitudinal study. Rheumatology 55 (2016), 2148–2155.
142. Guillevin, L, Hunsche, E, Denton, CP, et al., the DUO Registry Group. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry. Clin Exp Rheumatol 31:suppl 76 (2013), 71–80.
143. Sultan, N, Pope, JE, Clements, PJ, the Scleroderma Trials Study Group. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. Rheumatology 43 (2004), 472–478.
144. Valenzuela, A, Chung, L, Calcinosis: pathophysiology and management. Curr Opin Rheumatol 27 (2015), 542–548.
145. Nihtyanova, SI, Denton, CP, Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 6 (2010), 112–116.
146. Betteridge, ZE, Woodhead, F, Lu, H, et al. Brief report: anti-eukaryotic initiation factor 2B autoantibodies are associated with interstitial lung disease in patients with systemic sclerosis. Arthritis Rheumatol 68 (2016), 2778–2783.
147. Ghrénassia, E, Avouac, J, Khanna, D, et al. Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J Rheumatol 41 (2014), 99–105.
148. Salazar, GA, Assassi, S, Wigley, F, et al. Antinuclear antibody-negative systemic sclerosis. Semin Arthritis Rheum 44 (2015), 680–686.
149. Hoa, S, Hudson, M, Troyanov, Y, et al. the Canadian Scleroderma Research Group (CSRG) Australian Scleroderma Interest Group (ASIG), Genetics versus Environment in Scleroderma Outcome Study (GENISOS). Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. Medicine, 95, 2016, e4713.
150. Johnson, ME, Pioli, PA, Whitfield, ML, Gene expression profiling offers insights into the role of innate immune signaling in SSc. Semin Immunopathol 37 (2015), 501–509.
151. Pendergrass, SA, Lemaire, R, Francis, IP, Mahoney, JM, Lafyatis, R, Whitfield, ML, Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol 132 (2012), 1363–1373.
152. Johnson, ME, Mahoney, JM, Taroni, J, et al. Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts. PLoS One, 10, 2015, e0114017.
153. Chakravarty, EF, Martyanov, V, Fiorentino, D, et al. Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. Arthritis Res Ther, 17, 2015, 159.
154. Taroni, JN, Martyanov, V, Huang, CC, et al. Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures. Arthritis Res Ther, 17, 2015, 194.
155. Khan, K, Xu, S, Nihtyanova, S, et al. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 71 (2012), 1235–1242.
156. De Lauretis, A, Sestini, P, Pantelidis, P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 40 (2013), 435–446.
157. Khanna, D, Denton, CP, Jahreis, A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387 (2016), 2630–2640.
158. Maurer, B, Distler, A, Dees, C, et al. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. Ann Rheum Dis 72 (2013), 2039–2046.
159. Clark, KE, Lopez, H, Abdi, BA, et al. Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis. Arthritis Res Ther, 17, 2015, 73.
160. Quillinan, NP, McIntosh, D, Vernes, J, Haq, S, Denton, CP, Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial. Ann Rheum Dis 73 (2014), 56–61.
161. Rice, LM, Ziemek, J, Stratton, EA, et al. A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 67 (2015), 3004–3015.
162. Valentini, G, Iudici, M, Walker, UA, et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis 76 (2017), 270–276.
163. Hinchcliff, M, Huang, CC, Wood, TA, et al. Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol 133 (2013), 1979–1989.
164. Rice, LM, Padilla, CM, McLaughlin, SR, et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 125 (2015), 2795–2807.
165. Khanna, D, Berrocal, VJ, Giannini, EH, et al. The American College of Rheumatology Provisional Composite Response Index for clinical trials in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 68 (2016), 299–311.